Decentralizing Trials Puts Diversity At The Center Of Clinical Research

Underrepresentation in clinical trials presents serious challenges to public health. 

According to the U.S. Census Bureau, Non-Hispanic Whites represent 60.1% of the U.S. population, Hispanic/Latinos represent 18.5%, and Black/African Americans represent 13.4%. Yet, according to the FDA 2020 Drug Trial Snapshots, on average, Non-Hispanic Whites comprise 75% of traditional trial participants, while Hispanic/Latinos comprise only 11% and Black/African Americans comprise only 8% of participants.